Nivix Pharmaceuticals Gears Up for IPO, Receives 'B+' Rating from Infomerics Nepal

Nivix Pharmaceuticals Limited, an emerging player in Nepal's pharmaceutical manufacturing sector, is actively progressing with its plans to issue ordinary shares to the general public. As a crucial step in this process, the company has successfully obtained an 'Issuer Rating' of 'IRN B+ (Is)' [Single B Plus (Issuer)] from Infomerics Credit Rating Nepal Limited. This rating, while signifying a moderate degree of risk, indicates that the company's capacity to meet its financial obligations carries a high risk. According to the rating agency, entities receiving this grade are generally considered susceptible to external shocks and may face challenges in timely debt servicing (principal and interest payments).

The proposed Initial Public Offering (IPO) is a strategic move by Nivix Pharmaceuticals to fuel its ambitious business expansion plans and address its working capital requirements. Established as a private limited company in 2017, Nivix transitioned into a public limited entity in December 2024, paving the way for its public listing. The capital raised through the IPO is expected to play a pivotal role in reducing the company's existing debt burden and significantly enhancing its production capacity. The rating report underscores that the company's financial health could see substantial improvement if the IPO process is completed efficiently and the proceeds are utilized effectively and judiciously.

From a financial perspective, Nivix Pharmaceuticals is currently in a nascent stage of its operational journey. The company commenced commercial production only recently, in June 2024. Its revenue trajectory, however, shows promising growth from a low base. In the fiscal year 2080/81, the company recorded an operating income of just NPR 1 million. This figure surged to NPR 81 million in FY 2081/82, marking its first full year of commercial operations. Further demonstrating an upward trend, Nivix Pharmaceuticals generated NPR 113 million in revenue during the first nine months of the current fiscal year 2082/83, indicating a positive momentum in its market penetration and sales. Despite this revenue growth, the company's net profit remains in the negative territory, primarily due to high financial costs, particularly interest expenses. Another significant challenge for Nivix is its current capacity utilization, which stands at approximately 24%. Maximizing this utilization is crucial for achieving economies of scale and improving profitability.

Despite the prevailing financial indicators, Nivix Pharmaceuticals possesses several inherent strengths that offer a positive outlook for its future. The company is steered by a six-member Board of Directors, chaired by Kalidas Paudel, an individual with over two decades of extensive experience in the financial sector. Complementing this leadership are Managing Director Indra Baniya and Director Dr. Sujan Chandra Sigdel, both bringing more than 20 years of specialized expertise in the pharmaceuticals industry. This experienced management team is a critical asset, providing strategic direction and operational acumen. Furthermore, the company is rapidly expanding its product portfolio. By June 2026, Nivix Pharmaceuticals expects to have secured production permits for 109 products and marketing permits for 78. Currently, 72 products, including various tablets and capsules, are already available in the Nepali market, showcasing a robust pipeline and increasing market presence.

However, investors must also consider the inherent risks associated with the pharmaceutical sector and Nivix Pharmaceuticals specifically. The industry is inherently working capital-intensive, requiring substantial funds for operations, inventory, and research. A major risk factor for Nivix is its significant reliance on imported raw materials. Fluctuations in the prices of these raw materials and volatility in the US Dollar exchange rate can directly impact the company's cost structure and, consequently, its profitability. Moreover, the Nepali pharmaceutical market is characterized by intense competition from numerous well-established domestic and international players. This competitive landscape could pose challenges for new entrants like Nivix in terms of pricing strategies and market share acquisition. Adherence to stringent policies and quality standards set by the regulatory body, the Department of Drug Administration (DDA), also presents an ongoing challenge and requires continuous investment in quality control and compliance.

For investors considering Nivix Pharmaceuticals' IPO, this opportunity could be characterized as "high risk, high reward." While the company is currently operating at a loss, its aggressive business expansion trajectory and the presence of an experienced management team suggest a potential for positive future outcomes. Nevertheless, the 'B+' rating serves as a clear caution, advising investors to proceed with due diligence and a thorough understanding of the associated risks. The company's production plant is located in Vyas-10, Tanahun, with its corporate office in Pokhara. Notably, Nivix has managed to improve its debt-to-equity ratio (gearing ratio) to 1.04 times, a positive development compared to its past financial structure. Ultimately, the success of this investment will largely hinge on the company's ability to effectively manage its finances post-IPO, expand its market reach, and, critically, achieve full utilization of its production capacity to transition into profitability. Only then can investors expect to realize appropriate returns on their investment.